Jump to: navigation, search

Clinical data
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass267.28 g/mol

WikiDoc Resources for Voglibose


Most recent articles on Voglibose

Most cited articles on Voglibose

Review articles on Voglibose

Articles on Voglibose in N Eng J Med, Lancet, BMJ


Powerpoint slides on Voglibose

Images of Voglibose

Photos of Voglibose

Podcasts & MP3s on Voglibose

Videos on Voglibose

Evidence Based Medicine

Cochrane Collaboration on Voglibose

Bandolier on Voglibose

TRIP on Voglibose

Clinical Trials

Ongoing Trials on Voglibose at Clinical Trials.gov

Trial results on Voglibose

Clinical Trials on Voglibose at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Voglibose

NICE Guidance on Voglibose


FDA on Voglibose

CDC on Voglibose


Books on Voglibose


Voglibose in the news

Be alerted to news on Voglibose

News trends on Voglibose


Blogs on Voglibose


Definitions of Voglibose

Patient Resources / Community

Patient resources on Voglibose

Discussion groups on Voglibose

Patient Handouts on Voglibose

Directions to Hospitals Treating Voglibose

Risk calculators and risk factors for Voglibose

Healthcare Provider Resources

Symptoms of Voglibose

Causes & Risk Factors for Voglibose

Diagnostic studies for Voglibose

Treatment of Voglibose

Continuing Medical Education (CME)

CME Programs on Voglibose


Voglibose en Espanol

Voglibose en Francais


Voglibose in the Marketplace

Patents on Voglibose

Experimental / Informatics

List of terms related to Voglibose

Voglibose (INN and USAN) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix.

Glenmark is also producing voglibose under brand name vocarb.

Diabetes is chronic metabolic disorder characterised by hyperglycemia which is due to relative or absolute deficiency of insulin or insulin resistance.

PPHG is termed as Post Prandial Hyperglycemia which is primarily due to first phase insulin secretion. Alpha glucosidase inhibitor is one agent which delays the glucose absorption at the intestine level and thereby prevents sudden surge of glucose post meal.

There are three molecules which belong to this class namely, Acarbose, Miglitol and Voglibose. Voglibose is the latest molecule in this class. Voglibose scores over both Acarbose and MIglitol in terms of potency and side effect profile.

There are several trials supporting the use of Voglibose in the management of PPHG. Also, it has been established that it is PPHG not FPG which is marker of cardiovascular disorders associated with diabetes. So, controlling PPHG is imperative and Voglibose is indicated for the management of PPHG.

Sun Pharmaceuticals launched Voglibose 0.2 / 0.3 mg under the brand name VOLIBO.

External links